Key points are not available for this paper at this time.
Alopecia areata (AA) is a T-cell-mediated autoimmune disease characterized by nonscarring hair loss on the scalp and body. This is a retrospective single-centre study, performed at the trichology outpatient clinic of the University Federico II of Naples from January 2023 to January 2024, on a case series of 15 adolescent patients (12–17 years old) with severe AA who were treated for at least 24 weeks with off-label use of upadacitinib. Treatment with upadacitinib has a promising efficacy and safety profile in the treatment of severe AA in adolescent patients.
Picone et al. (Sat,) studied this question.